

[illegible]

**DMO**

[illegible]

[illegible]

				Araújo, R.S.; Santos, D.F.; Silva, G.A. The Role of the Retinal Pigment Epithelium and Müller Cells Secretome in Neovascular Retinal Pathologies. <i>Biochimie</i> <b>2018</b> , <i>155</i> , 104–108, doi:10.1016/j.biochi.2018.06.019.	Yes	Yes	Yes	CT	Yes	Yes	Yes							
19	Araujo	2018	Review															
				Rizzolo, L.J. Development and Role of Tight Junctions in the Retinal Pigment Epithelium. <i>International Review of Cytology</i> <b>2007</b> , <i>258</i> , 195–234, doi:10.1016/S0074-7696(07)58004-6.	Yes	Yes	Yes	CT	Yes	Yes	Yes							
20	Rizzolo	2007	Review															
				Omri, S.; Omri, B.; Savoldelli, M.; Jonet, L.; Thillaye-Goldenberg, B.; Thuret, G.; Gain, P.; Jeanny, J.C.; Crisanti, P.; Behar-Cohen, F. The Outer Limiting Membrane (OLM) Revisited: Clinical Implications. <i>Clinical Ophthalmology</i> <b>2010</b> , <i>4</i> , 183–195, doi:10.2147/opth.s5901.	Yes	Yes												
21	Omri	2010	Preclinical trial											Yes	Yes	Yes	Yes	Yes
				Sacconi, R.; Giuffrè, C.; Corbelli, E.; Borrelli, E.; Querques, G.; Bandello, F. Emerging Therapies in the Management of Macular Edema: A Review. <i>F1000Res</i> . 2019 Aug 12;8:F1000 Faculty Rev-1413. doi: 10.12688/f1000research.19198.1.	Yes	Yes	Yes	CT	Yes	Yes	Yes							
22	Sacconi	2019	Review															
				Miller, J.W.; le Couter, J.; Strauss, E.C.; Ferrara, N. Vascular Endothelial Growth Factor a in Intraocular Vascular Disease. <i>Ophthalmology</i> <b>2013</b> , <i>120</i> , 106–114, doi:10.1016/j.opth.2012.07.038.	Yes	Yes	Yes	CT	Yes	Yes	Yes							
23	Miller	2013	Review															
				Sodhi, A.; Ma, T.; Mervon, D.; Deshpande, M.; Jee, K.; Dinabandhu, A.; Vancel, J.; Lu, D.; Montaner, S. Angiopoietin-like 4 Binds Neuropilins and Cooperates with VEGF to Induce Diabetic Macular Edema. <i>Journal of Clinical Investigation</i> <b>2019</b> , <i>129</i> , 4593–4608, doi:10.1172/JCI120879.	Yes	Yes												
24	Sodhi	2019	Preclinical trial											Yes	Yes	Yes	Yes	Yes
				Fogli, S.; Mogavero, S.; Egan, C.G.; del Re, M.; Danesi, R. Pathophysiology and Pharmacological Targets of VEGF in Diabetic Macular Edema. <i>Pharmacological Research</i> <b>2016</b> , <i>103</i> , 149–157, doi:10.1016/j.phrs.2015.11.003.	Yes	Yes	Yes	CT	Yes	Yes	Yes							
25	Fogli	2016	Review															
				Rizzolo, L.J.; Peng, S.; Luo, Y.; Xiao, W. Integration of Tight Junctions and Claudins with the Barrier Functions of the Retinal Pigment Epithelium. <i>Progress in Retinal and Eye Research</i> 2011, <i>30</i> , 296–323.	Yes	Yes	Yes	CT	Yes	Yes	Yes							
26	Rizzolo	2011	Review															
				Beranova-Giorgianni, S.; Giorgianni, F. Proteomics of Human Retinal Pigment Epithelium (RPE) Cells. <i>Proteomes</i> <b>2018</b> , <i>6</i> , 22, doi:10.3390/proteomes6020022.	Yes	Yes	Yes	CT	Yes	Yes	Yes							
27	Beranova-Giorgianni	2018	Review															
				Ponnalagu, M.; Subramani, M.; Jayadev, C.; Shetty, R.; Das, D. Retinal Pigment Epithelium-Secretome: A Diabetic Retinopathy Perspective. <i>Cytokine</i> 2017, <i>95</i> , 126–135.	Yes	Yes	Yes	CT	Yes	Yes	Yes							
28	Ponnalagu	2017	Review															

[illegible]

39	Cunha-Vaz	2014	Review	Cunha-Vaz, J.; Ribeiro, L.; Lobo, C. Phenotypes and Biomarkers of Diabetic Retinopathy. <i>Progress in Retinal and Eye Research</i> 2014, 41, 90–111. doi: 10.1016/j.preteyeres.2014.03.003	Yes	Yes	Yes	CT	Yes	Yes	Yes					
40	Al-Shabrawey	2008	Precinical trial	Al-Shabrawey, M.; Rojas, M.; Sanders, T.; Behzadian, A.; El-Remessy, A.; Bartoli, M.; Parpia, A.K.; Liou, G.; Caldwell, R.B. Role of NADPH Oxidase in Retinal Vascular Inflammation. <i>Investigative Ophthalmology and Visual Science</i> 2008, 49, 3239–3244, doi:10.1167/iov.08-1755.	Yes	Yes						Yes	Yes	Yes	Yes	Yes
41	Li	2012	Precinical trial	Li, X.; Cai, Y.; Wang, Y.-S.; Shi, Y.-Y.; Hou, W.; Xu, C.-S.; Wang, H.-Y.; Ye, Z.; Yao, L.-B.; Zhang, J. Hyperglycaemia Exacerbates Choroidal Neovascularisation in Mice via the Oxidative Stress-Induced Activation of STAT3 Signalling in RPE Cells. <i>PLoS ONE</i> 2012, 7, e47600. doi:10.1371/journal.pone.0047600.	Yes	Yes						Yes	Yes	Yes	Yes	Yes
42	Huang	2011	Precinical trial	Huang, H.; Gandhi, J.K.; Zhong, X.; Wei, Y.; Gong, J.; Duh, E.J.; Vinore, S.A. TNF $\alpha$ Is Required for Late BRB Breakdown in Diabetic Retinopathy, and Its Inhibition Prevents Leukostasis and Protects Vessels and Neurons from Apoptosis. <i>Investigative Ophthalmology and Visual Science</i> 2011, 52, 1336–1344, doi:10.1167/iov.10-5768.	Yes	Yes						Yes	Yes	Yes	Yes	Yes
43	Zur	2019	Review	Zur, D.; Iglicki, M.; Loewenstein, A. The Role of Steroids in the Management of Diabetic Macular Edema. <i>Ophthalmic Research</i> 2019, 62, 231–236, doi: 10.1159/000499540	Yes	Yes	Yes	CT	Yes	Yes	Yes					
44	Chawan-Saad	2019	Review	Chawan-Saad, J.; Wu, M.; Wu, A.; Wu, L. Corticosteroids for Diabetic Macular Edema. <i>Taiwan Journal of Ophthalmology</i> 2019, 9, 233–242.	Yes	Yes	Yes	CT	Yes	Yes	Yes					
45	Monickaraj	2016	Precinical trial	Monickaraj, F.; McGuire, P.G.; Franco Nitta, C.; Ghosh, K.; Das, A. Cathepsin D: An $\alpha$ -M $\mu$ -Derived Factor Mediating Increased Endothelial Cell Permeability with Implications for Alteration of the Blood-Retinal Barrier in Diabetic Retinopathy. <i>FASEB Journal</i> 2016, 30, 1670–1682, doi:10.1096/fj.15-279802.	Yes	Yes						Yes	Yes	Yes	Yes	Yes
46	Hussain	2019	Review	Hussain, R.M.; Neiveem, A.E.; Kansara, V.; Harris, A.; Ciulla, T.A. Tie-2/Angiopoietin Pathway Modulation as a Therapeutic Strategy for Retinal Disease. <i>Expert Opinion on Investigational Drugs</i> 2019, 28, 861–869.	Yes	Yes	Yes	CT	Yes	Yes	Yes					
47	Jousseaume	2001	Precinical trial	Jousseaume, A.M.; Murata, T.; Tsujikawa, A.; Kirchhof, B.; Bursell, S.E.; Adamis, A.P. Leukocyte-Mediated Endothelial Cell Injury and Death in the Diabetic Retina. <i>American Journal of Pathology</i> 2001, 155, 147–152. doi:10.1016/S0002-9440(10)63952-1.	Yes	Yes						Yes	Yes	Yes	Yes	Yes
48	Ciulla	2003	Review	Ciulla, T.A.; Amador, A.G.; Zinman, B. <i>Diabetic Retinopathy and Diabetic Macular Edema Pathophysiology, Screening, and Novel Therapies</i> ; 2003;	Yes	Yes	Yes	CT	Yes	Yes	Yes					

49	Joussem	2004	Preclinical trial	Joussem, A.M.; Poulaki, V.; Le, M.L.; Koizumi, K.; Esser, C.; Janicki, H.; Schraermeyer, U.; Kociok, N.; Fauser, S.; Kirchhof, B.; et al. A Central Role for Inflammation in the Pathogenesis of Diabetic Retinopathy. <i>The FASEB Journal</i> <b>2004</b> , <i>18</i> , 1450–1452. doi:10.1096/fj.03-1476fje.	Yes	Yes													Yes	Yes	Yes	Yes	Yes
50	Bressler	2018	RCT	Bressler, N.M.; Beaulieu, W.T.; Glassman, A.R.; Blinder, K.J.; Bressler, S.B.; Jampol, L.M.; Melia, M.; Wells, J.A. Persistent Macular Thickening Following Intravitreal Aflibercept, Bevacizumab, or Ranibizumab for Central-Invololved Diabetic Macular Edema with Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. In Proceedings of the JAMA Ophthalmology; American Medical Association, March 1 2018; Vol. 136, pp. 257–269.	Yes	Yes													Yes	Yes			
51	Iglicki	2019	Comparative retrospective study	Iglicki, M.; Busch, C.; Zur, D.; Okada, M.; Mariussi, M.; Chhablani, J.K.; Cebeci, Z.; Fraser-Bell, S.; Chaikittmongkol, V.; Couturier, A.; et al. Dexamethasone Implant for Diabetic Macular Edema in Naive Compared with Refractory Eyes: The International Retina Group Real-Life 24-Month Multicenter Study: The Irgrel-Dex Study. <i>Retina</i> <b>2019</b> , <i>39</i> , 44–51, doi:10.1097/IAE.0000000000002196.	Yes	Yes													Yes	Yes	Yes	Yes	Yes
52	Maturi	2017	Review	Shah, S.U.; Maturi, R.K. Therapeutic Options in Refractory Diabetic Macular Oedema. <i>Drugs</i> <b>2017</b> , <i>77</i> , 481–492, doi:10.1007/s40265-017-0704-6.	Yes	Yes	Yes	CT		Yes	Yes	Yes											
53	Virgili	2018	Meta-analysis	Virgili, G.; Parravano, M.; Evans, J.R.; Gordon, I.; Lucenteforte, E. Anti-Vascular Endothelial Growth Factor for Diabetic Macular Oedema: A Network Meta-Analysis. <i>Cochrane Database of Systematic Reviews</i> <b>2018</b> , <i>2018</i> .	Yes	Yes	Yes	Yes		Yes	Yes	Yes											
54	The DRCRN	2015	RCT	Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. <i>New England Journal of Medicine</i> <b>2015</b> , <i>372</i> , 1193–1203, doi:10.1056/nejmoa1414264.	Yes	Yes													Yes	Yes	Yes	Yes	Yes
55	Karst	2019	Descriptive retrospective study	Karst, S.G.; Schuster, M.; Mitsch, C.; Meyer, E.L.; Kundi, M.; Scholda, C.; Schmidt-Erfurth, U.M. Atrophy of the Central Neuroretina in Patients Treated for Diabetic Macular Edema. <i>Acta Ophthalmologica</i> <b>2019</b> , <i>97</i> , e1054–e1061, doi:10.1111/aos.14173.	Yes	Yes															Yes	Yes	Yes
56	Willmann	2017	Comparative retrospective study	Willmann, G.; Nepomuceno, A.B.; Messias, K.; Barroso, L.; Scott, I.U.; Messias, A.; Jorge, R. Foveal Thickness Reduction after Anti-Vascular Endothelial Growth Factor Treatment in Chronic Diabetic Macular Edema. <i>International Journal of Ophthalmology</i> <b>2017</b> , <i>10</i> , 760–764, doi:10.18240/ijo.2017.05.17.	Yes	Yes													Yes	Yes	Yes	Yes	Yes

[illegible]

				Mehta, H.; Hennipin, C.; Gillies, M.C.; Nguyen, V.; Campain, A.; Fraser-Bell, S. Anti-Vascular Endothelial Growth Factor Combined with Intravitreal Steroids for Diabetic Macular Oedema. <i>Cochrane Database of Systematic Reviews</i> 2018, 2018, doi:10.1002/14651858.CD011599.pub2.	Yes	Yes	Yes	Yes	Yes	Yes	Yes				
65	Mehta	2018	Systematic Review	Boyer, D.S.; Yoon, Y.H.; Belfort, R.; Bandello, F.; Maturi, R.K.; Augustin, A.J.; Li, X.Y.; Cui, H.; Hashad, Y.; Whitcup, S.M. Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema. <i>Ophthalmology</i> 2014, 121, 1904–1914, doi:10.1016/j.optha.2014.04.024.	Yes	Yes									
66	Boyer	2014	RCT	Maturi, R.K.; Glassman, A.R.; Liu, D.; Beck, R.W.; Bhavsar, A.R.; Bressler, N.M.; Jampol, L.M.; Melia, M.; Punjabi, O.S.; Salehi-Had, H.; et al. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients with Persistent Diabetic Macular Edema: A DRCK Network Phase 2 Randomized Clinical Trial. <i>JAMA Ophthalmology</i> 2018, 136, 29–38, doi:10.1001/jamaophthol.2017.4914.	Yes	Yes					Yes	Yes	Yes	Yes	Yes
67	Maturi	2017	RCT	Stefánsson, E. The Therapeutic Effects of Retinal Laser Treatment and Vitrectomy. A Theory Based on Oxygen and Vascular Physiology. <i>Acta Ophthalmologica Scandinavica</i> 2001, 79, 435–440.	Yes	Yes					Yes	Yes	Yes	Yes	Yes
68	Stefánsson	2001	Review	Chin, H.S.; Park, T.S.; Moon, Y.S.; Oh, J.H. Difference in Clearance of Intravitreal Triamcinolone Acetonide between Vitrectomized and Nonvitrectomized Eyes. <i>Retina</i> 2005, 25, 556–560, doi:10.1097/00006982-200507000-00002.	Yes	Yes	Yes	CT	Yes	Yes	Yes				
69	Chin	2005	Preclinical trial	Yau, J.W.Y.; Rogers, S.L.; Kawasaki, R.; Lamoureux, E.L.; Kowalski, J.W.; Bek, T.; Chen, S.J.; Dekker, J.M.; Fletcher, A.; Grauslund, J.; et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. <i>Diabetes Care</i> 2012, 35, 556–564, doi:10.2337/dc11-1909.	Yes	Yes									
70	Yau	2012	Systematic Review	Ruiz-Loredo, A.Y.; López, E.; López-Colomé, A.M. Thrombin Promotes Actin Stress Fiber Formation in RPE through Rho/ROCK-Mediated MLC Phosphorylation. <i>Journal of Cellular Physiology</i> 2011, 226, 414–423, doi:10.1002/jcp.22347.	Yes	Yes	Yes	Yes	Yes	Yes	Yes				
ROCK															
71	Ruiz-Loredo	2011	Preclinical trial	Jahani, V.; Kavousi, A.; Mehri, S.; Karimi, G. Rho Kinase, a Potential Target in the Treatment of Metabolic Syndrome. <i>Biomedicine and Pharmacotherapy</i> 2018, 106, 1024–1030.	Yes	Yes									
72	Jahani	2018	Review		Yes	Yes	Yes	CT	Yes	Yes	Yes				



[illegible]

[illegible]

				Bryan, B.A.; Dennstedt, E.; Mitchell, D.C.; Walshe, T.E.; Noma, K.; Loureiro, R.; Saint-Geniez, M.; Campaigniac, J.; Liao, J.K.; Patricia, D.A. RhoA/ROCK Signalling Is Essential for Multiple Aspects of VEGF-mediated Angiogenesis. <i>The FASEB Journal</i> <b>2010</b> , <i>24</i> , 3186–3195, doi:10.1096/fj.09-145102.										
92	Bryan	2010	Preclinical trial		Yes	Yes				Yes	Yes	Yes	Yes	Yes
				Zhang, X.H.; Feng, Z.H.; Wang, X.Y. The ROCK Pathway Inhibitor Y-27632 Mitigates Hypoxia and Oxidative Stress-Induced Injury to Retinal Muller Cells. <i>Neural Regeneration Research</i> <b>2018</b> , <i>13</i> , 549–555, doi:10.4103/1673-5374.228761.	Yes	Yes				Yes	Yes	Yes	Yes	Yes
93	Zhang	2018	Preclinical trial		Yes	Yes				Yes	Yes	Yes	Yes	Yes
				Yokota, T.; Utsunomiya, K.; Taniguchi, K.; Gojo, A.; Kurata, H.; Tajima, N. Involvement of the Rho/Rho Kinase Signalling Pathway in Platelet-Derived Growth Factor BB-Induced Vascular Endothelial Growth Factor Expression in Diabetic Rat Retina. <i>Japanese Journal of Ophthalmology</i> <b>2007</b> , <i>51</i> , 424–430, doi:10.1007/s10384-007-0471-0.	Yes	Yes				Yes	Yes	Yes	Yes	Yes
94	Yokota	2007	Preclinical trial		Yes	Yes				Yes	Yes	Yes	Yes	Yes
				Rothschild, P.R.; Salah, S.; Berdugo, M.; Gélizé, E.; Delaunay, K.; Naud, M.C.; Klein, C.; Moulin, A.; Savoldelli, M.; Bergin, C.; et al. ROCK-1 Mediates Diabetes-Induced Retinal Pigment Epithelial and Endothelial Cell Blebbing: Contribution to Diabetic Retinopathy. <i>Scientific Reports</i> <b>2017</b> , <i>7</i> , 1–15, doi:10.1038/s41598-017-07329-y.	Yes	Yes				Yes	Yes	Yes	Yes	Yes
95	Rothschild	2017	Preclinical trial		Yes	Yes				Yes	Yes	Yes	Yes	Yes
				Arita, R.; Hata, Y.; Nakao, S.; Kita, T.; Miura, M.; Kawahara, S.; Zandi, S.; Almulki, L.; Tayyari, F.; Shimokawa, H.; et al. Rho Kinase Inhibition by Fasudil Ameliorates Diabetes-Induced Microvascular Damage. <i>Diabetes</i> <b>2009</b> , <i>58</i> , 215–226, doi:10.2337/db08-0762.	Yes	Yes				Yes	Yes	Yes	Yes	Yes
96	Arita	2009	Preclinical trial		Yes	Yes				Yes	Yes	Yes	Yes	Yes
				Chen, Y.L.; Ren, Y.; Xu, W.; Rosa, R.H.; Kuo, L.; Hein, T.W. Constriction of Retinal Venules to Endothelin-1: Obligatory Roles of ET A Receptors, Extracellular Calcium Entry, and Rho Kinase. <i>Investigative Ophthalmology and Visual Science</i> <b>2018</b> , <i>59</i> , 5167–5175, doi:10.1167/iovs.18-25369.	Yes	Yes				Yes	Yes	Yes	Yes	Yes
97	Chen	2018	Preclinical trial		Yes	Yes				Yes	Yes	Yes	Yes	Yes
				Rosa, R.H. Divergent Roles of Nitric Oxide and Rho Kinase in Vasomotor Regulation of Human Retinal Arterioles. <b>2009</b> , doi:10.1167/iovs.09-4391.	Yes	Yes				Yes	Yes	Yes	Yes	Yes
98	Rosa	2009	Preclinical trial		Yes	Yes				Yes	Yes	Yes	Yes	Yes
				Yamaguchi, M.; Nakao, S.; Arita, R.; Kaizu, Y.; Arima, M.; Zhou, Y.; Kita, T.; Yoshida, S.; Kimura, K.; Isobe, T.; et al. Vascular Normalization by ROCK Inhibitor: Therapeutic Potential of Ripasudil (K-115) Eye Drop in Retinal Angiogenesis and Hypoxia. <i>Investigative Ophthalmology and Visual Science</i> <b>2016</b> , <i>57</i> , 2264–2276, doi:10.1167/iovs.15-17411.	Yes	Yes				Yes	Yes	Yes	Yes	Yes
99	Yamaguchi	2016	Preclinical trial		Yes	Yes				Yes	Yes	Yes	Yes	Yes
				Nagaoka, T.; Hein, T.W.; Yoshida, A.; Kuo, L. Simvastatin Elicits Dilatation of Isolated Porcine Retinal Arterioles: Role of Nitric Oxide and Mevalonate-Rho Kinase Pathways., doi:10.1167/iovs.06-0856.	Yes	Yes				Yes	Yes	Yes	Yes	Yes
100	Nagaoka	2007	Preclinical trial		Yes	Yes				Yes	Yes	Yes	Yes	Yes

101	Fagerholm	2019	Review	Fagerholm, S.C.; Guenther, C.; Asens, M.L.; Savinko, T.; Uotila, L.M. Beta2-Integrins and Interacting Proteins in Leukocyte Trafficking, Immune Suppression, and Immunodeficiency Disease. <i>Frontiers in Immunology</i> <b>2019</b> , <i>10</i> , 1–10, doi:10.3389/fimmu.2019.00254.	Yes	Yes	Yes	CT	Yes	Yes	Yes						
102	Barreiro	2002	Preclinical trial	Barreiro, O.; Yáñez-Mó, M.; Serrador, J.M.; Montoya, M.C.; Vicente-Manzanares, M.; Tejedor, R.; Furthmayr, H.; Sánchez-Madrid, F. Dynamic Interaction of VCAM-1 and ICAM-1 with Moesin and Ezrin in a Novel Endothelial Docking Structure for Adherent Leukocytes. <i>Journal of Cell Biology</i> <b>2002</b> , <i>157</i> , 1233–1245, doi:10.1083/jcb.200112126.	Yes	Yes							Yes	Yes	Yes	Yes	Yes
103	Nourinia	2013	RCT	Nourinia, R.; Ahmadiéh, H.; Shahheidari, M.H.; Zandi, S.; Nakao, S.; Hafezi-Moghadam, A. Intravitreal Fasudil Combined with Bevacizumab for Treatment of Refractory Diabetic Macular Edema; a Pilot Study. <i>Journal of Ophthalmic and Vision Research</i> <b>2013</b> , <i>8</i> , 337–340.	Yes	Yes						Yes	Yes	Yes	Yes	Yes	
104	Ahmadiéh	2013	Prospective interventional case serie	Ahmadiéh, H.; Nourinia, R.; Hafezi-Moghadam, A. Intravitreal Fasudil Combined with Bevacizumab for Persistent Diabetic Macular Edema: A Novel Treatment. <i>JAMA Ophthalmology</i> <b>2013</b> , <i>131</i> , 923–924, doi:10.1001/jamaophthalmol.2013.143.	Yes	Yes									Yes	Yes	Yes
105	Van-Linden	2014	Review	van Linden, O.P.J.; Kooistra, A.J.; Leurs, R.; de Esch, I.J.P.; de Graaf, C. KLIFS: A Knowledge-Based Structural Database to Navigate Kinase-Ligand Interaction Space. <i>Journal of Medicinal Chemistry</i> <b>2014</b> , <i>57</i> , 249–277.	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
106	Zhao	2014	Review	Zhao, Z.; Wu, H.; Wang, L.; Liu, Y.; Knapp, S.; Liu, Q.; Gray, N.S. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? <i>ACS Chemical Biology</i> <b>2014</b> , <i>9</i> , 1230–1241.	Yes	Yes	Yes	CT	Yes	Yes	Yes						
107	Tanna	2018	Review	Tanna, A.P.; Johnson, M. Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension. <i>Ophthalmology</i> <b>2018</b> , <i>125</i> , 1741–1756.	Yes	Yes	Yes	CT	Yes	Yes	Yes						
108	Hoy	2018	Review	Hoy, S.M. Netarsudil Ophthalmic Solution 0.02%: First Global Approval. <i>Drugs</i> <b>2018</b> , <i>78</i> , 389–396, doi:10.1007/s40265-018-0877-7.	Yes	Yes	Yes	CT	Yes	Yes	Yes						
109	Jagasia	2021	CT (Phase IIa)	Jagasia, M.; Lazaryan, A.; Bachier, C.R.; Salhotra, A.; Weisdorf, D.J.; Zoghi, B.; Essell, J.; Green, L.; Schueller, O.; Patel, J.; et al. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> <b>2021</b> , JCO.20.02754, doi:10.1200/jco.20.02754.	Yes	Yes							Yes	Yes	Yes	Yes	Yes
110	Garnock-Jones	2014	Review	Garnock-Jones, K.P. Ripasudil: First Global Approval. <i>Drugs</i> <b>2014</b> , <i>74</i> , 2211–2215, doi:10.1007/s40265-014-0333-2.	Yes	Yes	Yes	CT	Yes	Yes	Yes						

111	Nakabayashi	2015	Precinical trial	Nakabayashi, S.; Kawai, M.; Yoshioka, T.; Song, Y.S.; Tani, T.; Yoshida, A.; Nagaoka, T. Effect of Intravitreal Rho Kinase Inhibitor Ripasudil (K-115) on Feline Retinal Microcirculation. <i>Experimental Eye Research</i> <b>2015</b> , <i>139</i> , 132–135, doi:10.1016/j.exer.2015.07.008.				Yes	Yes						Yes	Yes	Yes	Yes	Yes
112	Pakravan	2016	Prospective Interventional case serie	Pakravan, M.; Beni, A.N.; Ghahari, E.; Varshochian, R.; Yazdani, S.; Esfandiari, H.; Ahmadiieh, H. The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients with End-Stage Glaucoma. <i>American Journal of Therapeutics</i> <b>2016</b> , <i>24</i> , E676–E680, doi:10.1097/MJT.0000000000000362.				Yes	Yes						Yes	Yes	Yes	Yes	Yes
113	Mietzner	2019	Review	Mietzner, R.; Breunig, M. Causative Glaucoma Treatment: Promising Targets and Delivery Systems. <i>Drug Discovery Today</i> <b>2019</b> , <i>24</i> , 1606–1613.				Yes	Yes	Yes	CT	Yes	Yes	Yes					
114	Li	2013	Precinical trial	Li, M.; Yasumura, D.; Ma, A.A.K.; Matthes, M.T.; Yang, H.; Nielson, G.; Huang, Y.; Szoka, F.C.; LaVail, M.M.; Diamond, M.I. Intravitreal Administration of HA-1077, a ROCK Inhibitor, Improves Retinal Function in a Mouse Model of Huntington Disease. <i>PLoS ONE</i> <b>2013</b> , <i>8</i> , doi:10.1371/journal.pone.0056026.				Yes	Yes						Yes	Yes	Yes	Yes	Yes
115	Mietzner	2020	Precinical trial	Mietzner, R.; Kade, C.; Froemel, F.; Pauly, D.; Stamer, W.D.; Ohlmann, A.; Wegener, J.; Fuchshofer, R.; Breunig, M. Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy. <i>Pharmaceutics</i> <b>2020</b> , <i>12</i> , 1–22, doi:10.3390/pharmaceutics12080706.				Yes	Yes						Yes	Yes	Yes	Yes	Yes
116	Kita	2008	Precinical trial	Kita, T.; Hata, Y.; Arita, R.; Kawahara, S.; Miura, M.; Nakao, S.; Mochizuki, Y.; Enaida, H.; Goto, Y.; Shimokawa, H.; et al. Role of TGF-β in Proliferative Vitreoretinal Diseases and ROCK as a Therapeutic Target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> <b>2008</b> , <i>105</i> , 17504–17509, doi:10.1073/pnas.0804054105.				Yes	Yes						Yes	Yes	Yes	Yes	Yes
117	Ahmadiieh	2019	RCT	Ahmadiieh, H.; Nourinia, R.; Hafezi-Moghadam, A.; Sabbaghi, H.; Nakao, S.; Zandi, S.; Yaseri, M.; Tofighi, Z.; Akbarian, S. Intravitreal Injection of a Rho-Kinase Inhibitor (Fasudil) Combined with Bevacizumab versus Bevacizumab Monotherapy for Diabetic Macular Oedema: A Pilot Randomised Clinical Trial. <i>British Journal of Ophthalmology</i> <b>2019</b> , <i>103</i> , 922–927, doi:10.1136/bjophthalmol-2018-312244.				Yes	Yes	CT					Yes	Yes	Yes	Yes	Yes
118	Minami	2019	Comparative retrospective study	Minami, Y.; Song, Y. seok; Ishibazawa, A.; Omae, T.; Ro-mase, T.; ishiko, S.; Yoshida, A. Effect of Ripasudil on Diabetic Macular Edema. <i>Scientific Reports</i> <b>2019</b> , <i>9</i> , 5–9, doi:10.1038/s41598-019-40194-5.				Yes	Yes						Yes	Yes	Yes	Yes	Yes

119	Glendenning	2018	Preclinical trial	Glendenning, A.; Crews, K.; Sturdivant, J.; A del.ong, M.; Kopeczynski, C.; Lin, C.-W. Sustained Release, Biodegradable PEA Implants for Intravitreal Delivery of the ROCK/PKC Inhibitor AR-13503   IOVS   ARVO Journals. Invest. Ophthalmol. Vis. Sci. <b>2018</b> , 59, 5672.	Yes	Yes	Yes	Yes	Yes	Yes
120	Ding	2019	Preclinical trial	Ding, J.; Crews, K.; Carbajal, K.; Weksler, M.; Moore, L.; Carlson, E.C.; Lin, C.-W. Ocular Tissue Distribution and Duration of Release of AR-13503 Following Administration of AR-13503 Sustained Release Intravitreal Implant in Rabbits and Miniature Swine   IOVS   ARVO Journals. Invest. Ophthalmol. Vis. Sci. <b>2019</b> , 60, 5387.	Yes	Yes	Yes	Yes	Yes	Yes

RCT: Randomized Controlled Trial; CT: Clinical Trial